There is intense interest in developing therapeutic strategies for RAS proteins, the most frequently mutated oncoprotein family in cancer. Development of effective anti-RAS therapies will be aided by the greater appreciation of RAS isoform-specific differences in signaling events that support neoplastic cell growth. However, critical issues that require resolution to facilitate the success of these efforts remain. In particular, the use of well-validated anti-RAS antibodies is essential for accurate interpretation of experimental data. We evaluated 22 commercially available anti-RAS antibodies with a set of distinct reagents and cell lines for their specificity and selectivity in recognizing the intended RAS isoforms and mutants. Reliability varied substantially. For example, we found that some pan-or isoform-selective anti-RAS antibodies did not adequately recognize their intended target or showed greater selectivity for another; some were valid for detecting G12D and G12V mutant RAS proteins in Western blotting, but none were valid for immunofluorescence or immunohistochemical analyses; and some antibodies recognized nonspecific bands in lysates from "Rasless" cells expressing the oncoprotein BRAF V600E . Using our validated antibodies, we identified RAS isoform-specific siRNAs and shRNAs. Our results may help to ensure the accurate interpretation of future RAS studies.
INTRODUCTION
The three RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene family in cancer, with an overall 27% missense mutation frequency in all human cancers (COSMIC v80) (1) (2) (3) . RAS mutation frequency is highly tissue context-dependent, with highest frequencies observed in lung, colorectal, and pancreatic ductal adenocarcinoma (PDAC).
RAS genes encode four structurally and biochemically highly related 188 to 189 amino acid proteins (4) . KRAS encodes two proteins, KRAS4A and KRAS4B, owing to alternative fourth exon utilization (5) (6) (7) (8) . RAS proteins exhibit 82 to 90% overall amino acid sequence identity (9) and 93 to 99% sequence identity within the N-terminal G domain (residues 1 to 164) (10) . In sequences involved in interaction with the guanine nucleotide exchange factors and guanosine triphosphatase (GTPase)-activating proteins that regulate guanosine diphosphate (GDP)-guanosine triphosphate (GTP) cycling and in activation of downstream effectors (for example, RAF), this region is invariant. In contrast, RAS proteins show only 8% sequence identity in the C-terminal hypervariable region (HVR) (residues 165 to 184/185). RAS intracellular trafficking and membrane interactions are determined by the divergent HVR and Caax tetrapeptide motif-signaled posttranslational lipid modifications (prenylation and methylation), contributing to RAS isoform-distinct biological functions. One issue now recognized, yet still poorly understood, is that the four RAS protein isoforms, despite their near-identical structure and biochemistry, serve distinct roles as cancer drivers (3, 9) .
The three RAS genes are not mutated at comparable frequencies in human cancers. KRAS is by far the most commonly mutated (84%), followed by NRAS (12%) and HRAS (4%) (1) . In addition, there are tissue-specific preferences for the specific RAS gene mutated. For example, KRAS is exclusively the RAS isoform mutated in PDAC, whereas NRAS is the predominant (94%) isoform mutated in cutaneous melanoma, and HRAS mutations are favored (86%) in head and neck squamous cell carcinoma. Limited evidence that these frequencies reflect tissue-specific functions comes from mouse models of cancer. For example, Kras G12D , but not Nras G12D , promoted colon cancer development in Apc-deficient mice (11) . Expression of activated Kras G12V and Hras G12V under control of the same regulatory sequences resulted in different types of tumors (12) .
Cancer-associated RAS genes contain missense mutations that result in single amino acid substitutions; 99% are found at one of three mutational hotspots, glycine-12 (G12), glycine-13 (G13), or glutamine-61 (Q61) (1, 9, 13) . G12 mutations comprise 83% of all KRAS mutations, followed by G13 mutations (14%), whereas Q61 mutations are rare (2%). In striking contrast, Q61 is the predominant mutational hotspot in NRAS (62%), followed by G12 (23%), and then G13 (12%). These frequencies suggest that G12 and Q61 mutations may have distinct consequences for different RAS isoforms. That Nras Q61R but not Nras G12D potently caused melanoma development in Ink4a-deficient mice supports this possibility (14) . Finally, although there are six possible single-base missense mutations at each codon, the frequencies with which they occur are not uniform. It has also become evident that RAS mutant proteins exhibit distinct biochemical deficiencies (15, 16) . An emerging premise in the field is that the different RAS mutations are not created equal and that the identification of mutation-selective differences will identify unique vulnerabilities that can then be exploited to develop mutation-selective therapies (17) . The development of RAS inhibitors that are selective for one RAS mutation, G12C, represents this shift in the field (18, 19) .
Antibodies are essential reagents in biomedical research, but poorquality antibodies are a major cause of the "reproducibility crisis" in understanding protein function and in the pathway to new drugs (20) (21) (22) . This crisis, and the related need for better characterized and validated antibodies, is exemplified by a report that 47 of 53 landmark cancer research papers from the early 2000s could not be replicated (23) . It has been estimated that fewer than half of the 6000 commercially available antibodies recognize their advertised targets (21) and that $800 million annually is spent on poor-quality antibodies ($350 million in the United States alone) (22) . There are also numerous examples of antibody problems slowing medical progress. In 2009, a research group secured federal funding to stratify melanoma patient treatment regimens based on quantitative immunofluorescence (IF) staining of biopsy samples (24) . However, they were forced to abandon this project because subsequent lots of antibodies from the same source no longer generated the same results on the same tumor samples (20) . Furthermore, another research group spent 2 years, thousands of patient samples, and $500,000 before realizing that the antibody they had been using for early detection of pancreatic cancer was recognizing the wrong protein (20) , an astounding disappointment for pancreatic cancer patients, whose 5-year survival rate is an abysmal 8% (25) . Nevertheless, despite extensive efforts of organizations such as the International Working Group on Antibody Validation, two International Antibody Validation Meetings, and crowd-funded scientific websites such as www.antybuddy.com (26, 27) , the quality of commercially available antibodies and their degree of validation remain decidedly mixed.
With renewed interest in RAS and with new investigators entering the field (28, 29), we believe that now is an ideal time to revisit validation of RAS antibodies. To ensure the accuracy of our own studies and as a service to the field, we analyzed 22 commercially available RAS antibodies for their specificity and sensitivity in recognizing individual RAS isoforms. Our analyses demonstrate that the properties of many of these antibodies have not been accurately established. Our results support the likelihood that the conclusions from some RAS research have been compromised by misinterpretation of data because of faulty information regarding RAS antibody properties. Moving forward, we hope that our validation of antibodies for specific applications will facilitate greater reliability in future RAS studies.
RESULTS

Evaluation of RAS isoform selectivity against recombinant RAS proteins
We purified unprocessed wild-type full-length human KRAS4B, HRAS, and NRAS proteins from Escherichia coli. In addition, both unprocessed and processed (farnesylated, proteolyzed, and methylated) KRAS4B and KRAS4A were purified from insect cells, as we described (30) . Three concentrations of each purified RAS protein were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) to verify size and purity (Fig. 1A) . KRAS bands appear slightly more intense across the blot, likely because of their lysine-rich C-terminal HVR sequences detected by the negatively charged Coomassie staining method. Notably, unprocessed KRAS4A protein from insect cells purified as two species: a minority of the full-length protein and a major species that, based on mass spectrometry results, lacks the last five amino acids. Otherwise, RAS proteins were highly pure (>95%) and migrated at the expected molecular weight (MW) for full-length proteins.
We analyzed a panel of 22 commercially available RAS antibodies ( Table 1) that includes those most widely cited in the literature. Also included in this panel were four monoclonal antibodies generated against human KRAS4B protein by the National Cancer Institute (NCI) RAS Initiative at the Frederick National Laboratory for Cancer Research (FNLCR) that have not yet been used in any published studies. We interrogated each antibody for RAS isoform selectivity and sensitivity and asked whether Caax-signaled processing influenced recognition of KRAS proteins (Fig. 1, B to D) . Most antibodies recognized their intended target, but there were some exceptions.
No antibody described as having pan-RAS selectivity uniformly recognized all RAS isoforms. Ras10 (05-516) showed fairly equivalent recognition of all RAS isoforms and was not influenced by KRAS4B processing. However, another pan-RAS antibody (05-1072) was more selective for HRAS and for unprocessed KRAS4A than for other RAS proteins. Three of the four FNLCR-generated antibodies recognized all the RAS proteins, although the immunogen used was recombinant full-length KRAS4B (Fig. 1B) . Notably, the FNLCR CPTC-KRAS4B-2 antibody showed pan-RAS sensitivity that was superior to any of the commercially available pan-RAS antibodies we tested.
Two HRAS-specific (SC-520 and 18295-1-AP) and two NRASspecific (SC-31 and SC-519) antibodies showed strong selectivity for their intended targets, with no recognition of the other RAS isoforms (Fig. 1C) . However, one antibody intended to be NRAS-specific (10724-1-AP) only weakly recognized NRAS at the highest protein abundance and instead more effectively recognized other RAS isoforms.
We evaluated three commercially available KRAS4A/4B antibodies (Fig. 1D) . Two antibodies (SC-30 and OP24) recognized unprocessed and processed versions of both KRAS isoforms, whereas another (WH0003845M1) showed strong selectivity for KRAS4B with a higher affinity for unprocessed protein and did not recognize KRAS4A. We evaluated three KRAS4A-specific antibodies [16156-1-AP, SC-522 (C-17), and ABC1422], none of which recognized KRAS4B (Fig. 1D) . However, all three showed significantly stronger recognition of unprocessed than processed KRAS4A. This is not entirely surprising, given that the Caax-signaled posttranslational modifications are immediately adjacent to the major sequence differences between KRAS4A and KRAS4B and may therefore disrupt epitope recognition of antibodies generated against purified bacterial proteins that lack such modifications. The two KRAS4B-selective antibodies recognized purified KRAS4B but did not recognize KRAS4A. One of these (16155-1-AP) recognized both unprocessed and processed KRAS4B proteins with comparable signal strength (Fig. 1D) . In contrast, the other (SC-521) recognized only unprocessed KRAS4B protein, although the antibody was generated against the human KRAS4B C terminus. Processed KRAS4B may not be recognized because the antibody epitope overlaps with the cleaved Caax fragment that is removed during processing. (31) . Upon Kras deletion, these MEFs lack all Ras isoforms and become quiescent upon loss of all endogenous Ras activity. As was shown previously (31), we also determined that proliferation can be rescued by ectopic expression of activated BRAF V600E or of wild-type versions of human KRAS4A, KRAS4B, HRAS, or NRAS. We established MEF cell lines using clonal populations from cultures infected with lentivirus expression vectors encoding each gene. Therefore, total RAS protein across the cell lines is comparable but most likely not equivalent (Fig. 2) .
The results obtained with the three commercial pan-RAS antibodies in cell lines largely mirrored those using recombinant RAS proteins ( Fig. 2A) . Antibody 05-516 readily detected all RAS isoforms, albeit more weakly for KRAS4B. However, it also weakly detected a band in the Rasless MEFs expressing BRAF V600E that comigrated with HRAS and NRAS, likely a RAS-related protein. As described above, three of the four FNLCR-generated anti-KRAS4B antibodies display pan-RAS specificity, with CPTC-KRAS4B-2 showing stronger and equivalent recognition of all RAS isoforms, no detection of any proteins in the~21-kDa range in the Rasless MEFs expressing BRAF
V600E
, and faint recognition of other high-MW cellular proteins (Fig. 2B) . CPTC-KRAS4B-3 displayed similar pan-RAS reactivity and may better recognize NRAS. However, this antibody also weakly recognized a band in Rasless MEFs expressing BRAF V600E that migrates just above all the RAS isoforms; depending on the properties of the SDS-PAGE used to resolve cell lysates, this minor band may or may not be a concern in Western blotting applications.
Although both HRAS antibodies showed high specificity for the HRAS isoform, one (18295-1-AP) recognized few other cellular proteins, whereas the second (SC-520) also recognized numerous others (Fig. 2C) . The NRAS antibody SC-31 showed high specificity for NRAS and no recognition of any~21-kDa bands in Rasless MEFs expressing BRAF V600E (Fig. 2D ). Of three putative KRAS4A/4B antibodies evaluated, both SC-30 and OP24 recognized both KRAS4A and KRAS4B, and WH0003845M1 was highly selective for KRAS4B (Fig. 2E) . However, on the basis of the much stronger recognition of recombinant KRAS4A protein by SC-30 and OP24 (Fig. 1D) , we suspect that neither antibody would provide an accurate determination of how expression of the two KRAS isoforms at the RNA level is related to isoform expression at the protein level.
One KRAS4A-specific antibody (16156-1-AP) appeared to recognize KRAS4A but additionally recognized a closely comigrating band in Rasless MEFs expressing BRAF V600E (Fig. 2F ). In contrast, two other KRAS4A-specific antibodies selectively recognized KRAS4A, but not KRAS4B, with no detection of any~21-kDa bands in Rasless MEFs expressing BRAF V600E (Fig. 2F ). Although both KRAS4B antibodies specifically detected purified recombinant proteins (Fig. 1D ), neither detected KRAS4B in cell lysates but strongly recognized numerous nonspecific proteins (Fig. 2G) . Instead, our data indicate that although WH0003845M1 is described as capable of detecting both KRAS4A and KRAS4B, it is the best available reagent for selective detection of KRAS4B. We conclude that there are many experimental conditions under which even antibodies commonly used in the literature may lead to erroneous interpretations. 
RAS isoform detection in a human cell line
Our analyses in Rasless MEFs assessed detection of exogenously expressed human RAS and also revealed highly variable nonspecific recognition of mouse proteins. To assess detection of endogenous human RAS proteins and to evaluate nonspecific reactivity in human cells, we also evaluated several antibodies using lysates of human embryonic kidney (HEK) 293T cells (Fig. 3A) . Two pan-RAS antibodies, 05-1072 and 05-516, recognized all RAS isoforms but also recognized other bands. The FNLCR antibody (CPTC-KRAS4B-2) that showed strong pan-RAS reactivity in Rasless MEFs expressing any RAS isoform without additional~21-kDa bands in Rasless MEFs expressing BRAF V600E ( Fig. 2B ) also showed strong recognition of human RAS proteins and minimal recognition of nonspecific human proteins. Neither HRAS-specific antibody detected any~21-kDa band in HEK293T cells, indicating that these cells do not express significant endogenous HRAS. The NRAS-selective antibody SC-31 strongly recognized endogenous NRAS, with essentially no nonspecific reactivity.
Collectively, our results using the three commercially available KRAS4A/4B antibodies in all three model systems enable us to conclude that HEK293T cells express only KRAS4B and that WH0003845M1 is superior to the two commercial KRAS4B-selective antibodies in recognizing endogenous human KRAS4B. Similarly, despite the strong detection by 16156-1-AP of a~21-kDa band in HEK293T cells, we conclude, based on our results using this antibody in Rasless MEFs, that this band likely represents detection of RAS-related proteins (such as RRAS isoforms). Finally, the lack of detection of any~21-kDa band in HEK293T cells by the KRAS4A-specific antibodies SC-522 and ABC1442, coupled with the results from Rasless MEFs, validates both as excellent reagents for selective detection by Western blotting of endogenous human KRAS4A but not KRAS4B protein. We suggest that such parallel analyses, using purified human RAS proteins, Rasless MEFs, and human cells, can more definitively identify the true specificity of RAS antibodies than any one system alone.
Use of RNA interference for antibody validation in human tumor cell lines Other experimental strategies that assist in the validation of the RAS isoform selectivity of antibodies use genetic knockdown using short hairpin RNA (shRNA) and small interfering RNA (siRNA) to selectively target each RAS gene. Currently, no shRNA has been reported that can selectively silence each KRAS splice variant. Using a panel of human non-small cell lung carcinoma (NSCLC) cell lines, we first stably infected each line with lentivirus vectors encoding a nonspecific sequence or two distinct targeted sequences (table S1) for human HRAS, NRAS, or KRAS (Fig. 3B) . Western blots on the resulting cell lysates with our isoform-selective KRAS4A/4B and NRAS antibodies validated in Rasless MEFs expressing KRAS or NRAS (OP24 and SC-31, respectively). For comparison, we included an HRAS-selective antibody, SC-520, which failed in our validation experiments, to illustrate complications that may arise upon recognition of closely migrating nonspecific reactivity.
The protein abundances detected by the KRAS4A/4B and NRAS antibodies were strongly reduced in cells stably expressing shRNA targeting KRAS and NRAS, respectively (Fig. 3B) . In contrast,~21-kDa bands were not reduced in cells stably expressing shRNA targeting HRAS and probed with the SC-520 antibody, suggesting that these HRAS-targeted shRNAs were not effective in silencing HRAS expression. However, the same analyses with a well-validated second HRAS-selective antibody, 18295-1-AP, did show strong suppression of HRAS protein levels (Fig. 3, C and D) . Thus, the apparent detection of HRAS protein by SC-520 likely reflects instead its strong detection of non-RAS proteins that migrate near HRAS (Fig. 2C) . Table 2 provides a list of the isoform-specific, pan-RAS, and pan-KRAS (KRAS4A/4B) antibodies that we have validated for Western blot applications, based on the above experiments.
With our validated antibodies, we could initially identify shRNAs that were selective for human KRAS or NRAS, without displaying off-target effects on other RAS isoforms. However, both of the original shRNAs targeting HRAS had isoform-specific off-target effects (Fig. 3C) . To better identify an effective and selective HRAS shRNA, we further infected the panel of NSCLC lines with five additional HRAS shRNAs (Fig. 3D ) and validated shRNAs that selectively suppressed HRAS. Our results using isoform-specific shRNAs are summarized in table S1. Similarly, we evaluated isoform specificity of siRNAs used to target different RAS isoforms in two RAS mutant rhabdomyosarcoma cell lines. The protein levels detected by the specific antibodies were reduced in cells transiently transfected with the appropriate siRNAs (Fig. 3E) . In this instance, HRAS knockdown is clearly visible with the SC-520 antibody, suggesting that the nonspecific bands that comigrate with HRAS in NSCLC lines are not expressed in rhabdomyosarcoma lines (Fig. 3 , E and F), stressing that our antibody validations are context-and cell type-dependent. Notably, NRAS protein expression is reduced with KRAS siRNA1, HRAS siRNA2 decreases NRAS expression, and NRAS siRNA2 and siRNA3 reduce HRAS expression. As done with the shRNAs, we further transfected these cells with additional KRAS, HRAS, and NRAS siRNAs and validated those that selectively suppress the correct isoform without targeting other RAS isoforms. Our results using isoformspecific siRNAs, as well as a list of all siRNA and shRNA binding sites, are summarized in the Supplementary Materials (table S2 and fig. S1 , respectively).
Analysis of RAS G12D and G12V mutation-specific antibodies
We also tested two commercially available G12 mutant-specific RAS antibodies for their ability to recognize ectopically expressed mutant human KRAS4B in rescued Rasless MEFs expressing different mutant KRAS proteins and endogenous mutant KRAS in human KRAS mutant cell lines (Fig. 4) . These antibodies were very specific for the indicated mutant proteins. No background bands were detected in any of the lysates, even at extended exposure times. Notably, our data indicate that KRAS protein levels in Rasless MEFs expressing different mutant KRAS proteins are comparable to endogenous levels in the established cancer cell lines. However, although very specific for their targets, these mutation-specific antibodies were considerably less sensitive than most of the isoform-specific antibodies. We included only KRAS mutant cell lines along with our controls in these experiments, but these antibodies are also advertised to detect the G12D and G12V mutant forms of HRAS and NRAS.
RAS antibodies unsuitable for IF of endogenous RAS proteins
We investigated whether any of the isoform-and mutant-specific RAS antibodies validated for use in Western blotting could also be used for IF detection of RAS proteins in Rasless MEFs (Fig. 5A ). Our initial, baseline metric for suitability in IF was the lack of a significant signal in Rasless MEFs expressing BRAF V600E . Only one, the NRAS antibody SC-31, met this criterion (Fig. 5A) . Notably, adherent Rasless MEFs expressing NRAS cover large surface areas when cultured on plastic or glass. Upon detaching these cells with trypsin, they are similar in size to Rasless MEFs expressing other RAS proteins in suspension. Moreover, the NRAS antibody selectively stained Rasless MEFs expressing NRAS but not Rasless MEFs expressing KRAS4A, KRAS4B, or HRAS (Fig. 5B) . The subcellular distribution of the signal was consistent with that of NRAS in our previous reports (32, 33) . However, not all cells in each culture of Rasless MEFs expressing NRAS stained positively, presumably because of differing levels of NRAS expression.
Despite their utility in Western blotting, both RAS mutationspecific antibodies also failed to be suitable for IF (Fig. 5C ). The G12D-specific antibody picked up substantial background in Rasless MEFs expressing BRAF
V600E
. Although the G12V-specific antibody did not appreciably stain Rasless MEFs expressing BRAF V600E , it did stain Rasless MEFs expressing any other RAS isoform. We suspect that the use of these antibodies in IF may be limited by their low sensitivity, as shown in our Western blots, making it difficult to distinguish endogenous levels of RAS from background signals in individual cells. Similarly, our attempts to detect endogenous wild-type and mutant NRAS in human cancer cell lines by IF, using the same SC-31 antibody that selectively stained Rasless MEFs expressing NRAS, were unsuccessful. We first validated by Western blotting that we could deplete the endogenous NRAS signal in cancer cells harboring wild-type NRAS (A375 cells) or mutant NRAS (Q61K) (SBC12 cells). Despite near-complete NRAS knockdown (Fig. 6A) , the IF signal remained unchanged in each case (Fig. 6B) .
It is widely appreciated that antibodies selected for utility in one application may not perform well in another (27) . Western blots are performed under denaturing conditions, whereas IF detects proteins in more native conformations. Thus, although disappointing, it may not be entirely surprising that we have been unable to identify RAS antibodies suitable for both Western blotting and IF.
DISCUSSION
There is now a greater appreciation that there are RAS isoform-distinct biological roles in normal and neoplastic cells and that there are mutationdistinct functional consequences of these differences for RAS function (9) . Research that aims to successfully address these differences requires the use of antibody reagents that have been rigorously validated for specificity and for utility in designated experimental applications. We recognize that the degree of validation of commercially available RAS antibodies is highly variable and that rigorous validation is not feasible for most research laboratories to perform on their own. The NCI RAS Initiative was established in part to address such gaps in the field (29) .
We completed studies that critically assessed 22 commercially available RAS antibodies, including those most widely used in the literature. Our goals were to identify potential limitations of each antibody, to rigorously validate antibodies for use in the field in specific applications, and, ultimately, to establish how accurately it is possible to interpret data acquired using each antibody. A critical component of our analyses was the utilization of a unique panel of Rasless MEFs expressing BRAF V600E or other RAS isoforms. With this well-validated panel, which we established at the NCI RAS Initiative, coupled with our analyses of recombinant unprocessed and processed human KRAS4A/4B proteins and by using shRNA vectors targeting each RAS gene, we were able to very rigorously assess RAS specificity and isoform selectivity under different experimental conditions. We have identified antibodies that selectively recognize each of the four human RAS proteins in human cancer cells, thereby identifying a set of RAS antibodies that can be used with confidence in future studies using Western blot analyses. Our survey did not identify RAS antibodies useful for other experimental applications such as IF or IHC. Consistent with perceptions of the antibody field in general (20-22), we found a broad spectrum of RAS antibody quality, from poor to excellent. Overall, most of these antibodies displayed their vendordescribed specificities, but several vendors provided incomplete or overstated information that may lead to misinterpretation of data.
Given the high overall amino acid sequence identity of RAS proteins (9), many antibodies generated against one specific RAS isoform will also recognize other RAS isoforms. For example, although monoclonal antibody CPTC-KRAS4B-2 was generated against KRAS4B, the name is misleading in that it suggests KRAS4B selectivity. Instead, we found that CPTC-KRAS4B-2 was the most effective pan-RAS antibody available and can provide a useful reagent to determine overall total RAS protein expression in cells. However, this antibody may also recognize other~21-kDa small GTPases with sequence similarity to RAS. Because ectopic expression of other small GTPases cannot restore the growth of Rasless MEFs (31), we do not have reagents to address potential antibody selectivity for such proteins with similar rigor as done here for RAS. Conversely, one polyclonal antibody generated against recombinant NRAS poorly recognized recombinant NRAS, showed stronger recognition of other recombinant RAS proteins, and failed to detect NRAS in our panel of rescued Rasless MEFs expressing other RAS isoforms. Thus, although it did identify a~21-kDa band in HEK293T cells, we suspect that the detected band is not NRAS. Finally, although the product information provided with this antibody showed that it recognizes only a single~21-kDa band in HEK293 cell lysates, with no recognition of other cellular proteins, our analyses in both Rasless MEFs and HEK293T cells found very significant nonspecific reactivity. These and other examples emphasize the critical value of Rasless MEFs in evaluating RAS antibody selectivity and utility in different experimental applications. Of the two KRAS splice variants, KRAS4B has been by far the most studied in the cancer field, due in large part to availability of reagents and a widely held perception that the KRAS4B splice variant is the predominant KRAS protein expressed in human tumor cells (5) . However, in the absence of antibodies capable of distinguishing KRAS4A and KRAS4B, this perception was based on early studies of KRAS expression at the level of mRNA, not protein. Ironically, the very first discovery of KRAS as an oncogene was of the Kirsten murine sarcoma virus, which encodes a G12-mutated rat KRas4A protein (34) . Furthermore, our studies found that 30 of 30 human cancer cell lines express both KRAS4A and KRAS4B mRNA and that, in colorectal carcinoma tissues, KRAS4A and KRAS4B transcripts are similarly abundant (6). Our analyses here did identify useful antibodies for selective detection of KRAS4A and KRAS4B proteins. Regarding KRAS4B-selective antibodies, we found that the two commercially available antibodies, although clearly selective when evaluated using recombinant proteins, did not effectively recognize cell-expressed KRAS4B protein in Rasless MEFs. One antibody did detect~21-kDa bands, but the equivalent detection of such bands in the Rasless MEFs expressing BRAF V600E demonstrates that this antibody does not detect cellular KRAS4B expression. Instead, we found that the best KRAS4B-selective antibody was one described as detecting both KRAS4A and KRAS4B. We did validate two useful KRAS4A-selective antibodies, with each having distinct nonspecific activities that do not compromise their application in Western blots but likely limit their usefulness in other applications. Currently, whether KRAS4A and KRAS4B serve distinct driver roles in cancer is not known. To date, the relative expression of the two KRAS splice variants has been determined only at the RNA level. Validated KRAS splice variant-selective antibodies will provide crucial reagents to accurately address this issue. Furthermore, using our validated antibodies, we identified shRNA constructs selective for each RAS isoform that can assist in determining the specificity of additional antibodies.
Finally, we validated two mutation-specific antibodies for Western blot detection of RAS proteins with G12D or G12V mutations (which comprise 59% of all KRAS mutations), supporting the feasibility of developing additional antibodies selective for other common RAS mutations. Current assays to detect GTP-bound RAS are not amenable to IHC evaluation of patient tumor tissue. Unfortunately, these mutationselective antibodies were also not useful for IHC analyses of formalinfixed, paraffin-embedded or frozen tissue from two cases harboring previously identified KRAS G12D and KRAS G12V mutations, although Western blot analyses of tissue from the same two cases confirmed expression of the G12D or G12V mutant RAS proteins ( fig. S2 ). Thus, these antibodies cannot selectively measure activated RAS in patient tissue.
In summary, we have performed comprehensive analyses of the selectivity of a large panel of RAS antibodies and achieved our goal of validating antibodies that are useful for Western blot detection of each of the four RAS proteins as well as of the two KRAS mutations most prevalent in cancer. Our studies also emphasize the need for wellvalidated RAS antibodies for other experimental applications, in particular for IF analyses of endogenous RAS proteins, where our current knowledge of the spatial distribution of RAS proteins has relied exclusively on the study of exogenously expressed proteins. With the possible exception of a validated NRAS-selective antibody, we did not identify RAS antibodies useful for IF analyses. Although many commercially available RAS antibodies are described as being useful for IF (Table 1) , our findings stress that more rigorous validation of antibody utility in specific applications, beyond simply detecting signal, needs to be done. We did not evaluate the usefulness of RAS antibodies for IP or (with the exception of G12 mutation-specific antibodies) for IHC, although the inability of the antibodies we tested to perform well in IF suggests that they may also not work well in IP applications. We did not evaluate all commercially available RAS antibodies. Nevertheless, our Western blot results can serve as a resource and guide for further qualifying RAS antibodies for additional applications.
MATERIALS AND METHODS
E. coli expression and purification of human RAS proteins Recombinant proteins were expressed as His6-MBP (maltose-binding protein)-tev (tobacco etch virus)-RAS fusion proteins in E. coli [pRare, BL21 Star (DE3)] and purified, as we described (35) . After proteolytic cleavage of the N-terminal tags, the final proteins generated were GlyGlySerGly-KRAS4B (2 to 188), Gly-HRAS (1 to 189), and Gly-NRAS (2 to 189). Protein concentrations were determined by UV 280 (ultraviolet absorbance at 280 nm) using an extinction coefficient of 19,865 M −1 cm −1 (11,920 from protein and 7945 from GDP) (36). Insect cell expression and purification of KRAS4A and KRAS4B Expression and purification of processed GlyGly-Hs.KRAS4A (2 to 189) and GlyGly-Hs.KRAS4B (2 to 188) were performed, as we described previously, using a bacmid engineered to coexpress farnesyltransferase subunit a (FNTA) and farnesyltransferase subunit b (FNTB) (35) . Expression of nonprocessed GlyGly-Hs.KRAS4A and GlyGly-Hs.KRAS4B followed the same protocol except that the expression constructs were cloned into the standard bacmid. Purification of processed KRAS4B was performed, as we described (35), whereas processed KRAS4A was purified using a modified protocol that added an anion exchange step after the initial capture from lysate. Nonprocessed KRAS4B was purified, as we described previously (30) .
Establishment of Rasless MEFs with isoform-specific RAS protein production A clonal panel of MEF cell lines containing single-transgene alleles was generated using the Rasless MEF system developed by Drosten et al. (31) . MEFs null for both Hras and Nras (provided by M. Barbacid) were treated with 600 nM 4-hydroxytamoxifen (4-OHT) for 9 to 11 days to remove the endogenous floxed KRAS gene. Cells lacking all endogenous Ras proteins arrest in G1 but resume proliferation upon lentiviral delivery of an ERK (extracellular signal-regulated kinase) MAPK (mitogenactivated protein kinase) pathway activating gene (for example, RAS or BRAF). Alternatively, cell line pools were generated through lentiviral transduction and antibiotic selection followed by treatment with 4-OHT and single-cell cloning. A single-cell clone was validated for each transgene. Confirmation of endogenous Kras gene removal was performed by Western blotting and sequencing.
RAS antibody generation
Purified unprocessed full-length wild-type KRAS4B (30) was submitted for antibody generation at Precision Antibody. Candidate clones were screened at the Antibody Characterization Laboratory (ACL; FNLCR) following procedures outlined on the antibody portal website (http:// antibodies.cancer.gov). Four candidates were selected based on reactivity by Western blot on a Wes instrument (ProteinSimple) and using the IP mass spectrometry method developed by the ACL. All antibodies and characterization data can be found on the ACL web portal, and antibodies and hybridomas are available through the DSHB (University of Iowa).
SDS-PAGE
Each purified RAS protein was diluted in 1× NuPAGE LDS loading buffer (Invitrogen), containing 25 mM tris(2-carboxyethyl)phosphine (TCEP; Sigma-Aldrich) to final protein concentrations of 3, 1, and 0.3 mg per 10 ml and applied to 10 to 20% gradient Criterion 26-well tris-HCl precast gels (Bio-Rad) in 1× tris-glycine-SDS running buffer. BenchMark protein ladder size standards (Thermo Fisher Scientific) flank each set of proteins. Gels were stained with SimplyBlue SafeStain (Thermo Fisher Scientific) and then imaged in a Fujifilm LAS-3000 equipped with an LAS-4000 CCD camera.
Western blots
For purified protein, each RAS protein was diluted in 1× NuPAGE LDS loading buffer containing 25 mM TCEP to final protein concentrations of 10, 1, and 0.1 ng per 10 ml and denatured by heating to 70°C for 10 min. Western blots were performed, as described previously (37) . Cells were lysed in 1% Triton detergent buffer and assayed for protein content using the bicinchoninic acid assay (Pierce Biotechnology). shRNA knockdowns of specific RAS isoforms Lentivirus virus-like particles expressing shRNAs targeted against different RAS transcripts were produced in HEK293T cells by transfection of a 4:3:1 ratio of NRAS (or nonspecific) shRNA plasmid/psPAX2/ pMD2.G and a 1:3 ratio of DNA/FuGENE 6 (Promega). Sequences targeted by each shRNA are provided in table S1.
Immunofluorescent laser scanning confocal microscopy All rescued Rasless MEFs expressing BRAF V600E or RAS isoforms were plated at a density of 4 × 10 4 cells in 12-well no. 1.5 MatTek plates with 14-mm coverslips (MatTek Corporation) and grown for 24 to 48 hours before fixing in 2% paraformaldehyde for 15 min at room temperature, 4% paraformaldehyde for 5 min at room temperature, or 100% methanol for 20 min at −20°C. Paraformaldehyde-fixed cells were permeabilized with 0.1% Triton X-100 in 1× phosphate-buffered saline for 15 min. All cells were then incubated in blocking buffer (Rockland) containing 0.1% Triton X-100 for 45 min at room temperature. Cells were incubated overnight in 1:100 dilutions of each RAS antibody. Cells were then incubated in 1:300 goat anti-mouse or goat anti-rabbit Alexa Fluor 488 (Invitrogen) in blocking buffer + 0.1% Triton X-100. Ten minutes before completion of secondary antibody incubation, a 1:100 dilution of DAPI (50 mg/ml; Thermo Fisher Scientific) was added to each well to stain nuclei. After washing, cells were imaged in a Zeiss LSM700 scanning confocal microscope with a 40× oil immersion lens. Images were analyzed using ZEN blue software (Carl Zeiss AG). Changes in fixation method did not affect localization, except with anti-HRAS. Methanol fixation of Rasless MEFs expressing HRAS led to loss of nuclear staining in both Rasless MEFs expressing BRAF V600E or NRAS. Otherwise, the nonspecific signal was preserved. All images shown are from cells fixed in 2% paraformaldehyde, except for WH0003845M1 KRAS images, which were from methanol-fixed cells. For co-localization experiments in melanoma lines, A375 and SBC12 cells were fixed in 2% paraformaldehyde for 15 min at room temperature. To visualize the plasma membrane, we added wheat germ agglutinin Alexa Fluor 647 conjugate (W33466, Thermo Fisher Scientific) labeling solution (5 mg/ml in 250 ml) to each well and incubated it for 10 min at 37°C. For endoplasmic reticulum or Golgi labeling, anti-PDI (MA3-019, Invitrogen) or anti-GM130 (610823) (BD Biosciences) was incubated on the cells overnight (1:300), followed by goat anti-mouse Alexa Fluor 568 for 45 min at room temperature. Cells were washed and imaged in a Zeiss LSM700 with a 63× oil immersion lens. Images were analyzed using ZEN blue software.
IHC on formalin-fixed and frozen sections of human tumor tissues IHC was performed on 4-mm-thick formalin-fixed, paraffin-embedded de-identified patient tumor sections using the Discovery XT automated system (Ventana Medical Systems). Sections were mounted on charged glass slides and baked at 60°C for 1 hour before heat-induced antigen retrieval was performed using standard CC1 (Cell Conditioning 1 solution). Slides were incubated with G12D (14429)-or G12V (14412)-selective antibodies for either 2 hours at room temperature (UltraMap protocol) or 1 hour with heat (DABMap protocol). Chromogenic detection was done with the DABMap kit or the UltraMap DAB anti-Rb kit. Frozen sections (4 mm thick) were fixed in neutral buffered formalin for 10 min before the assay was performed on the Discovery Ultra automated system (Ventana Medical Systems). Slides underwent 36 min of CC1 treatment before incubation with G12D or G12V antibodies, titrated at 1:100, for 60 min at 37°C. Detection was completed with the DABMap kit.
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